Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the biochemical progression free survival (bPFS) of SABR
alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with
oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.